GlaxoSmithKline
Supplier Diversity
5 Moore Drive
PO Box 13398
Durham, NC 27709-3398

Tel. 919.315.3781
Fax: 336.369.8974

www.gsk.com

VIA ELECTRONIC MAIL (AGO.highcostprescriptiondrugs@vermont.gov)

June 14, 2021

Office of The Attorney General
State of Vermont
Attn: TJ Donovan, Attorney General
109 State Street
Montpelier, VT 05609

RE: Notice of Emergency Use Authorization for New Drug

Dear Attorney General Donovan:

GlaxoSmithKline ("GSK") is issuing this notice as a courtesy to inform you that on May 27, 2021 we received approval from FDA under an Emergency Use Authorization (EUA) for a new prescription drug -- SOTROVIMAB. GSK made the product commercially available on June 11, 2021.

The new drug, listed below with its respective NDC, is:

(1) SOTROVIMAB, SOTROVIMAB 500 mg Solution Vial (NDC: 00173-0901-86*)

*This is a provisional NDC that will be updated upon BLA approval.

In accordance with State law, GSK will submit further information as required for new drug approvals, when FDA grants and approves the biologics license application (BLA) for the product. Please let me know if you have any questions about this notice or the product referenced herein.

Regards,

Jennifer Smith
Pricing Operations Manager
Payer Marketing
US

Email Jennifer.3.smith@gsk.com